Agios Pharmaceuticals, Inc. Press Releases

AGIO 
$110.18
*  
1.27
1.17%
Get AGIO Alerts
*Delayed - data as of Jul. 31, 2015  -  Find a broker to begin trading AGIO now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By







Agios Appoints Maykin Ho, Ph.D., to its Board of Directors
6/23/2015 4:01:00 PM - GlobeNewswire


Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency
6/12/2015 6:00:00 AM - Business Wire
▼-10.12 % Price Change since this news event. The Volume Ratio is 8.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies
6/12/2015 5:55:00 AM - Business Wire
▼-10.12 % Price Change since this news event. The Volume Ratio is 8.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies
6/12/2015 5:50:00 AM - Business Wire
▼-10.12 % Price Change since this news event. The Volume Ratio is 8.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia
6/10/2015 4:39:00 PM - Business Wire
▼-11.17 % Price Change since this news event. The Volume Ratio is 1.29.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Agios to Present Clinical and Preclinical Data at the 20th Congress of the European Hematology Association
5/21/2015 8:06:00 AM - Business Wire
▼-5.88 % Price Change since this news event. The Volume Ratio is 0.71.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day